Thursday, December 16, 2010

Teach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Schools

$1.8 Million Grant Will Enable Teach For America to Recruit and Train More Math and Science Graduates to Join the Teaching Corps

THOUSAND OAKS, Calif. and NEW YORK, Dec. 16, 2010 /PRNewswire via COMTEX/—Teach For America and the Amgen Foundation today announced the renewal of their partnership to advance math and science education in America’s underserved public schools. Under this partnership, the Amgen Foundation pledged $1.8 million to increase the number of outstanding math and science graduates who join Teach For America’s teaching corps by 2013. This new grant brings the total support from Amgen Foundation to more than $7 million since 2004.

Read the rest of this entry

Posted in Press Releases

Monday, December 13, 2010

XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer

Pivotal Phase 3 ‘147 Study Meets Primary Endpoint

First Bone-Targeted Therapy to Delay the Onset of Bone Metastases in Patients with Prostate Cancer

THOUSAND OAKS, Calif., Dec. 13, 3010, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ‘147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first occurrence of bone metastases (secondary endpoint). Overall survival was similar between the XGEVA and placebo groups (secondary endpoint).

Read the rest of this entry

Posted in Press Releases

Friday, December 10, 2010

Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS

XGEVA Long Term Extension Data Demonstrate XGEVA Delayed Skeletal-Related Events by Five Months Compared to Zometa®

Additional Data Shows Advanced Breast Cancer Patients Treated with XGEVA Experienced Less Disruption of Daily Functioning from Pain and Improvements in Health-Related Quality of Life

THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA™ (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa(R) (zoledronic acid). These results underscore the efficacy profile of XGEVA in preventing skeletal-related events (SREs) in patients with bone metastases from advanced breast cancer, as well as explore XGEVA’s impact on pain and quality of life outcomes, compared to Zometa. These new results were presented at the 33rd Annual San Antonio Breast Cancer Symposium.

Read the rest of this entry

Posted in Press Releases

Wednesday, December 08, 2010

Amgen to Present at Deutsche Bank's 2010 BioFEST

THOUSAND OAKS, Calif., Dec. 8, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will participate in Deutsche Bank’s 2010 BioFEST on Wednesday, Dec. 15, 2010, at the Four Seasons in Boston, beginning at 10:00 a.m.  Eastern Time. Roy Baynes, M.D., Ph.D., vice president of Global Development and Arvind Sood, vice president, Investor Relations will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Wednesday, December 08, 2010

Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition

THOUSAND OAKS, Calif. and WASHINGTON, Dec. 8, 2010 /PRNewswire via COMTEX/ —The Amgen Foundation and Ashoka’s Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients’ voices to improve health outcomes.

Read the rest of this entry

Posted in Press Releases